Article
H396P mutation in chronic myeloid leukaemia patient on nilotinib - A case report.
The Malaysian journal of pathology - 1 Apr 2021
Jamali N S, Raja Sabudin R Z A, Alauddin H, Ithnin A, Tumian N R, Jalil N, Awai R, Abu Amis S H, Shuib S
Abstract excerpt
INTRODUCTION: The advent of BCR-ABL1-targeted therapy with the tyrosine kinase inhibitor (TKI), for example, imatinib and nilotinib, marked a turning point in the therapy of chronic myeloid leukaemia (CML). However, a substantial proportion of patients experience primary or secondary disease resistance to TKI. There are multifactorial causes contributing to the treatment failure of which BCR-ABL1 kinase domain...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.